Skip to main content
Top
Published in: Pathology & Oncology Research 2/2008

01-06-2008 | Original Paper

Tumor Characteristics in Screen-Detected and Symptomatic Breast Cancers

Authors: István Pálka, Gyöngyi Kelemen, Katalin Ormándi, György Lázár, Tibor Nyári, László Thurzó, Zsuzsanna Kahán

Published in: Pathology & Oncology Research | Issue 2/2008

Login to get access

Abstract

The natural course of early breast cancer has changed as a result of the introduction of mammographic screening. The present aim was a prospective analysis of screen-detected and symptomatic operable breast cancers in the era of mammographic service screening. The mode of detection (screen-detected, symptomatic or interval cancer), the type of mammographic image and other characteristics (the invasive tumor size, histological tumor type, grade, nodal, hormone receptor and HER2 status and the presence of lymphovascular invasion) of 569 invasive breast cancers were studied. Screen-detected cancers were significantly more frequently of grade I, <10 mm of size and node-negative (p < 0.001, respectively). Symptomatic/interval cancers were significantly more frequently of grade 3, >20 mm of size (p < 0.001), and exhibited lymphovascular invasion (p = 0.001). Screening-detection of the tumor favored breast-conserving surgery, sentinel lymph node biopsy and the avoidance of chemotherapy (p < 0.001). Cancers associated with casting-type calcifications on the mammogram were typically of ductal type (p = 0.043), of grade 2–3, estrogen receptor and progesterone receptor-negative and HER2-positive (p < 0.001). Interval cancers occurred significantly more often at a younger age and remained mammographically occult as compared with other cancers. Mammographic screen-detected cancers demonstrate more favorable prognostic features, and need less extensive treatment than symptomatic or interval cancers. The mammographic appearance of the tumor reflects its biological behavior, and this should be considered in the management optimization.
Literature
1.
go back to reference Tabar L, Fagerberg G, Duffy SW et al. (1989) The Swedish two-county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43:107–114PubMedCrossRef Tabar L, Fagerberg G, Duffy SW et al. (1989) The Swedish two-county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43:107–114PubMedCrossRef
2.
go back to reference Tabar L, Yeng M-F, Vitak B et al. (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405–1410PubMedCrossRef Tabar L, Yeng M-F, Vitak B et al. (2003) Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:1405–1410PubMedCrossRef
3.
go back to reference The Swedish Organised Service Screening Evaluation Group (2006) Reduction of breast cancer mortality from organised service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 15:45–51CrossRef The Swedish Organised Service Screening Evaluation Group (2006) Reduction of breast cancer mortality from organised service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 15:45–51CrossRef
4.
go back to reference Miller AB, Baines C, To T et al. (1992) Canadian national breast screening study. 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 147:1459–1476 Miller AB, Baines C, To T et al. (1992) Canadian national breast screening study. 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 147:1459–1476
5.
go back to reference Kerlikowske K, Grady D, Rubin SM et al. (1995) Efficacy of screening mammography. A meta-analysis. JAMA 273:149–154 Kerlikowske K, Grady D, Rubin SM et al. (1995) Efficacy of screening mammography. A meta-analysis. JAMA 273:149–154
6.
go back to reference Cronin KA, Feuer EJ, Clarke LD, et al. (2006) Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000. Comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst 36:112–121 Cronin KA, Feuer EJ, Clarke LD, et al. (2006) Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000. Comparison of mortality results from the CISNET breast cancer base case analysis. J Natl Cancer Inst 36:112–121
7.
go back to reference Moody-Ayers SY, Wells CK, Feinstein AR (2000) ”Benign” tumors and ”early detection” in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med 160:1109–1115PubMedCrossRef Moody-Ayers SY, Wells CK, Feinstein AR (2000) ”Benign” tumors and ”early detection” in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med 160:1109–1115PubMedCrossRef
8.
go back to reference Klemi PJ, Joensuu H, Tikkanen S et al. (1992) Aggressiveness of breast cancers found with and without screening. Br Med J 304:467–469CrossRef Klemi PJ, Joensuu H, Tikkanen S et al. (1992) Aggressiveness of breast cancers found with and without screening. Br Med J 304:467–469CrossRef
9.
go back to reference Klemi PJ, Parvinen I, Pylkkanen L et al. (2003) Significant improvement in breast cancer survival through population-based mammography screening. Breast 12:308–313PubMedCrossRef Klemi PJ, Parvinen I, Pylkkanen L et al. (2003) Significant improvement in breast cancer survival through population-based mammography screening. Breast 12:308–313PubMedCrossRef
10.
go back to reference Anttinen J, Kautiainen H, Kuopo T (2006) Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients. Br J Cancer 94:147–151PubMedCrossRef Anttinen J, Kautiainen H, Kuopo T (2006) Role of mammography screening as a predictor of survival in postmenopausal breast cancer patients. Br J Cancer 94:147–151PubMedCrossRef
11.
go back to reference Joensuu H, Lehtimäki T, Holli K et al. (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064–1073PubMedCrossRef Joensuu H, Lehtimäki T, Holli K et al. (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064–1073PubMedCrossRef
12.
go back to reference Shen Y, Yang Y, Inoues LYT et al. (2005) Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203PubMedCrossRef Shen Y, Yang Y, Inoues LYT et al. (2005) Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203PubMedCrossRef
13.
go back to reference Gill PG, Farshid G, Luke CG et al. (2005) Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13:15–22CrossRef Gill PG, Farshid G, Luke CG et al. (2005) Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 13:15–22CrossRef
14.
go back to reference Ernst MF, Voogd AC, Goebergh JWW et al. (2004) Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 100:1337–1344PubMedCrossRef Ernst MF, Voogd AC, Goebergh JWW et al. (2004) Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 100:1337–1344PubMedCrossRef
15.
go back to reference Tabar L, Dean PB, Kaufman CS et al. (2000) A new era in the diagnosis of breast cancer. Surg Oncol Clinics NA 9:233–277 Tabar L, Dean PB, Kaufman CS et al. (2000) A new era in the diagnosis of breast cancer. Surg Oncol Clinics NA 9:233–277
16.
go back to reference Tabar L, Chen TH, Yen AM, et al. (2004) Mammographic tumor features can predict long-term outcomes reliably in women with 1–14-mm invasive breast carcinoma. Cancer 101:1745–1759PubMedCrossRef Tabar L, Chen TH, Yen AM, et al. (2004) Mammographic tumor features can predict long-term outcomes reliably in women with 1–14-mm invasive breast carcinoma. Cancer 101:1745–1759PubMedCrossRef
17.
go back to reference Thurfjell E, Thurfjell MG, Lindgren A (2001) Mammographic finding as predictor of survival in 1–9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 67:177–180CrossRef Thurfjell E, Thurfjell MG, Lindgren A (2001) Mammographic finding as predictor of survival in 1–9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 67:177–180CrossRef
18.
go back to reference Alexander MC, Yankaskas BC, Biesemier KW (2006) Association of stellate mammographic pattern with survival in small invasive breast tumors. Am J Roentgenol 187:29–73CrossRef Alexander MC, Yankaskas BC, Biesemier KW (2006) Association of stellate mammographic pattern with survival in small invasive breast tumors. Am J Roentgenol 187:29–73CrossRef
19.
go back to reference Peacock C, Given-Wilson RM, Duffy SW (2004) Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator? Clin Radiol 59:165–170PubMedCrossRef Peacock C, Given-Wilson RM, Duffy SW (2004) Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator? Clin Radiol 59:165–170PubMedCrossRef
20.
go back to reference Pálka I, Ormándi K, Gaál S et al. (in press) Casting-type calcifications on the mammogram indicate a higher probability of early relapse and death among operable high-risk breast cancer patients. Acta Oncol Pálka I, Ormándi K, Gaál S et al. (in press) Casting-type calcifications on the mammogram indicate a higher probability of early relapse and death among operable high-risk breast cancer patients. Acta Oncol
21.
go back to reference Perry NM (2001) Quality assurance in the diagnosis of breast disease. EUSOMA Working Party. Eur J Cancer 37:159–172 Perry NM (2001) Quality assurance in the diagnosis of breast disease. EUSOMA Working Party. Eur J Cancer 37:159–172
22.
go back to reference Ravdin PM, Siminoff LA, Davis GJ et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991PubMed Ravdin PM, Siminoff LA, Davis GJ et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991PubMed
23.
go back to reference Olivotto IA, Bajdik CD, Ravdin PM, et al. (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef Olivotto IA, Bajdik CD, Ravdin PM, et al. (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef
24.
go back to reference Porter PJ, El-Bastawissi AZ, Mandelson MT et al. (1999) Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028PubMedCrossRef Porter PJ, El-Bastawissi AZ, Mandelson MT et al. (1999) Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028PubMedCrossRef
25.
go back to reference Gilliland FD, Joste N, Stauber PM et al. (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743–749PubMedCrossRef Gilliland FD, Joste N, Stauber PM et al. (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743–749PubMedCrossRef
26.
go back to reference Crosier M, Scott D, Wilson RG et al. (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682–2688PubMed Crosier M, Scott D, Wilson RG et al. (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682–2688PubMed
27.
go back to reference Porter GJ, Evans AJ, Cornford EJ et al. (2007) Influence of mammographic parenchymal pattern in screen-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. Am J Roentgenol 188:676–683CrossRef Porter GJ, Evans AJ, Cornford EJ et al. (2007) Influence of mammographic parenchymal pattern in screen-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. Am J Roentgenol 188:676–683CrossRef
28.
go back to reference Porter GJ, Evans AJ, Burrell HC et al. (2007) NHSBSP type 1 interval cancers: a scientifically valid grouping? Clin Radiol 62:262–267PubMedCrossRef Porter GJ, Evans AJ, Burrell HC et al. (2007) NHSBSP type 1 interval cancers: a scientifically valid grouping? Clin Radiol 62:262–267PubMedCrossRef
29.
go back to reference Zunzunegui RG, Chung MA, Oruwari J et al. (2003) Casting-type calcifications with invasion and high-grade ductal carcinoma in situ. Arch Surg 138:537–540PubMedCrossRef Zunzunegui RG, Chung MA, Oruwari J et al. (2003) Casting-type calcifications with invasion and high-grade ductal carcinoma in situ. Arch Surg 138:537–540PubMedCrossRef
Metadata
Title
Tumor Characteristics in Screen-Detected and Symptomatic Breast Cancers
Authors
István Pálka
Gyöngyi Kelemen
Katalin Ormándi
György Lázár
Tibor Nyári
László Thurzó
Zsuzsanna Kahán
Publication date
01-06-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9010-7

Other articles of this Issue 2/2008

Pathology & Oncology Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine